Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer

The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2013-01, Vol.2013 (2013), p.1-7
Main Authors: Li, Xue, Zhang, Nan, Wang, Guoqing, Wang, Rong, Liu, Yunde
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - economics
Carcinoembryonic antigen
Case-Control Studies
Classification
Cost-Benefit Analysis
Developing countries
Disease
Female
Hospitals
Humans
LDCs
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - economics
Lung Neoplasms - pathology
Male
Medical imaging
Middle Aged
Mortality
Neoplasm Proteins - blood
Neoplasm Proteins - economics
ROC Curve
Sensitivity and Specificity
Tumors
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333
cites cdi_FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333
container_end_page 7
container_issue 2013
container_start_page 1
container_title BioMed research international
container_volume 2013
creator Li, Xue
Zhang, Nan
Wang, Guoqing
Wang, Rong
Liu, Yunde
description The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal serum marker combination panel that benefits the patients and the medical management system as well, four routine lung cancer serum markers (SCCA, NSE, CEA, and CYFRA21-1) were evaluated individually and in combination. Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis. As expected, combinations of these tumor markers improved their sensitivity for lung cancer and different combination panels had their own usefulness. NSE + CEA + CYFRA21-1 was the optimal combination panel with highest Youden’s index (0.64), higher sensitivity (75.76%), and specificity (88.57%), which can aid the clinical diagnosis of lung cancer. Nevertheless, the most cost-effective combination was SCCA + CEA, which can be used to screen the high-risk group.
doi_str_mv 10.1155/2013/195692
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3792518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3097328311</sourcerecordid><originalsourceid>FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333</originalsourceid><addsrcrecordid>eNqN0cFrFDEUBvAgii1rT94l4EUs0-YlM8nORSjDWgtberAePIVM5qVNnUlqMrPS_95Zty7VU3NJID8-XvIR8hbYCUBVnXIG4hTqStb8BTnkAspCQgkv92chDshRzndsXkuQrJavyQEvQaol8EPyvel98Nb0dLUx_WRGHwM1oaNNzGOxcg7t6DcYMGd6Fkz_kH2m0dGvmKaBXk9DTPTSpB-YMvWBrqdwQxsTLKY35JUzfcajx31Bvn1eXTdfivXV-UVzti5sJeVYtBZFXSLUXDEpS8uXgrO2lWXdddBChWiMlFx1UHGHXIm2dVZ2znXWgBFCLMinXe791A7YWQxjMr2-T34w6UFH4_W_N8Hf6pu40ULVvILlHPDhMSDFnxPmUQ8-W-x7EzBOWUNZKmB1KdlzqBBK1nMpC_L-P3oXpzT_4B8FlVQA2-GPd8qmmHNCt58bmN4WrLcF613Bs3739Kl7-7fOGXzcgVsfOvPLPy8NZ4LOPMFMSCXFb7KPtoI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1441567113</pqid></control><display><type>article</type><title>Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer</title><source>Wiley-Blackwell Open Access Collection</source><source>Publicly Available Content Database</source><creator>Li, Xue ; Zhang, Nan ; Wang, Guoqing ; Wang, Rong ; Liu, Yunde</creator><contributor>Reams, Romonia Renee</contributor><creatorcontrib>Li, Xue ; Zhang, Nan ; Wang, Guoqing ; Wang, Rong ; Liu, Yunde ; Reams, Romonia Renee</creatorcontrib><description>The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal serum marker combination panel that benefits the patients and the medical management system as well, four routine lung cancer serum markers (SCCA, NSE, CEA, and CYFRA21-1) were evaluated individually and in combination. Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis. As expected, combinations of these tumor markers improved their sensitivity for lung cancer and different combination panels had their own usefulness. NSE + CEA + CYFRA21-1 was the optimal combination panel with highest Youden’s index (0.64), higher sensitivity (75.76%), and specificity (88.57%), which can aid the clinical diagnosis of lung cancer. Nevertheless, the most cost-effective combination was SCCA + CEA, which can be used to screen the high-risk group.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2013/195692</identifier><identifier>PMID: 24167812</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - economics ; Carcinoembryonic antigen ; Case-Control Studies ; Classification ; Cost-Benefit Analysis ; Developing countries ; Disease ; Female ; Hospitals ; Humans ; LDCs ; Lung cancer ; Lung Neoplasms - blood ; Lung Neoplasms - diagnosis ; Lung Neoplasms - economics ; Lung Neoplasms - pathology ; Male ; Medical imaging ; Middle Aged ; Mortality ; Neoplasm Proteins - blood ; Neoplasm Proteins - economics ; ROC Curve ; Sensitivity and Specificity ; Tumors ; Young Adult</subject><ispartof>BioMed research international, 2013-01, Vol.2013 (2013), p.1-7</ispartof><rights>Copyright © 2013 Rong Wang et al.</rights><rights>Copyright © 2013 Rong Wang et al. Rong Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Rong Wang et al. 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333</citedby><cites>FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/1441567113/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1441567113?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,25753,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24167812$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Reams, Romonia Renee</contributor><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Wang, Guoqing</creatorcontrib><creatorcontrib>Wang, Rong</creatorcontrib><creatorcontrib>Liu, Yunde</creatorcontrib><title>Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal serum marker combination panel that benefits the patients and the medical management system as well, four routine lung cancer serum markers (SCCA, NSE, CEA, and CYFRA21-1) were evaluated individually and in combination. Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis. As expected, combinations of these tumor markers improved their sensitivity for lung cancer and different combination panels had their own usefulness. NSE + CEA + CYFRA21-1 was the optimal combination panel with highest Youden’s index (0.64), higher sensitivity (75.76%), and specificity (88.57%), which can aid the clinical diagnosis of lung cancer. Nevertheless, the most cost-effective combination was SCCA + CEA, which can be used to screen the high-risk group.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - economics</subject><subject>Carcinoembryonic antigen</subject><subject>Case-Control Studies</subject><subject>Classification</subject><subject>Cost-Benefit Analysis</subject><subject>Developing countries</subject><subject>Disease</subject><subject>Female</subject><subject>Hospitals</subject><subject>Humans</subject><subject>LDCs</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - economics</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical imaging</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Neoplasm Proteins - blood</subject><subject>Neoplasm Proteins - economics</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqN0cFrFDEUBvAgii1rT94l4EUs0-YlM8nORSjDWgtberAePIVM5qVNnUlqMrPS_95Zty7VU3NJID8-XvIR8hbYCUBVnXIG4hTqStb8BTnkAspCQgkv92chDshRzndsXkuQrJavyQEvQaol8EPyvel98Nb0dLUx_WRGHwM1oaNNzGOxcg7t6DcYMGd6Fkz_kH2m0dGvmKaBXk9DTPTSpB-YMvWBrqdwQxsTLKY35JUzfcajx31Bvn1eXTdfivXV-UVzti5sJeVYtBZFXSLUXDEpS8uXgrO2lWXdddBChWiMlFx1UHGHXIm2dVZ2znXWgBFCLMinXe791A7YWQxjMr2-T34w6UFH4_W_N8Hf6pu40ULVvILlHPDhMSDFnxPmUQ8-W-x7EzBOWUNZKmB1KdlzqBBK1nMpC_L-P3oXpzT_4B8FlVQA2-GPd8qmmHNCt58bmN4WrLcF613Bs3739Kl7-7fOGXzcgVsfOvPLPy8NZ4LOPMFMSCXFb7KPtoI</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Li, Xue</creator><creator>Zhang, Nan</creator><creator>Wang, Guoqing</creator><creator>Wang, Rong</creator><creator>Liu, Yunde</creator><general>Hindawi Publishing Corporation</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer</title><author>Li, Xue ; Zhang, Nan ; Wang, Guoqing ; Wang, Rong ; Liu, Yunde</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - economics</topic><topic>Carcinoembryonic antigen</topic><topic>Case-Control Studies</topic><topic>Classification</topic><topic>Cost-Benefit Analysis</topic><topic>Developing countries</topic><topic>Disease</topic><topic>Female</topic><topic>Hospitals</topic><topic>Humans</topic><topic>LDCs</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - economics</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical imaging</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Neoplasm Proteins - blood</topic><topic>Neoplasm Proteins - economics</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Xue</creatorcontrib><creatorcontrib>Zhang, Nan</creatorcontrib><creatorcontrib>Wang, Guoqing</creatorcontrib><creatorcontrib>Wang, Rong</creatorcontrib><creatorcontrib>Liu, Yunde</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Xue</au><au>Zhang, Nan</au><au>Wang, Guoqing</au><au>Wang, Rong</au><au>Liu, Yunde</au><au>Reams, Romonia Renee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>2013</volume><issue>2013</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>The detection of serum tumor markers is valuable for the early diagnosis of lung cancer. Tumor markers are frequently used for the management of cancer patients. However, single markers are less efficient but marker combinations increase the cost, which is troublesome for clinics. To find an optimal serum marker combination panel that benefits the patients and the medical management system as well, four routine lung cancer serum markers (SCCA, NSE, CEA, and CYFRA21-1) were evaluated individually and in combination. Meanwhile, the costs and effects of these markers in clinical practice in China were assessed by cost-effectiveness analysis. As expected, combinations of these tumor markers improved their sensitivity for lung cancer and different combination panels had their own usefulness. NSE + CEA + CYFRA21-1 was the optimal combination panel with highest Youden’s index (0.64), higher sensitivity (75.76%), and specificity (88.57%), which can aid the clinical diagnosis of lung cancer. Nevertheless, the most cost-effective combination was SCCA + CEA, which can be used to screen the high-risk group.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>24167812</pmid><doi>10.1155/2013/195692</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2013-01, Vol.2013 (2013), p.1-7
issn 2314-6133
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3792518
source Wiley-Blackwell Open Access Collection; Publicly Available Content Database
subjects Adult
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - economics
Carcinoembryonic antigen
Case-Control Studies
Classification
Cost-Benefit Analysis
Developing countries
Disease
Female
Hospitals
Humans
LDCs
Lung cancer
Lung Neoplasms - blood
Lung Neoplasms - diagnosis
Lung Neoplasms - economics
Lung Neoplasms - pathology
Male
Medical imaging
Middle Aged
Mortality
Neoplasm Proteins - blood
Neoplasm Proteins - economics
ROC Curve
Sensitivity and Specificity
Tumors
Young Adult
title Clinical Evaluation and Cost-Effectiveness Analysis of Serum Tumor Markers in Lung Cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T20%3A09%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Evaluation%20and%20Cost-Effectiveness%20Analysis%20of%20Serum%20Tumor%20Markers%20in%20Lung%20Cancer&rft.jtitle=BioMed%20research%20international&rft.au=Li,%20Xue&rft.date=2013-01-01&rft.volume=2013&rft.issue=2013&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2013/195692&rft_dat=%3Cproquest_pubme%3E3097328311%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c566t-bce394e19270664c28320bb649dd1b15eeaa6627d152fe273bbfc6dffdca1a333%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1441567113&rft_id=info:pmid/24167812&rfr_iscdi=true